Valuation: AstraZeneca PLC

Market Cap 249B 215B 201B 185B 347B 23,697B 353B 2,360B 926B 11,878B 935B 915B 39,267B P/E 2026 *
20.6x
P/E 2027 * 17.9x
Enterprise Value 269B 232B 217B 199B 375B 25,580B 381B 2,547B 1T 12,821B 1,009B 987B 42,386B EV / Sales 2026 *
4.25x
EV / Sales 2027 * 3.91x
Free-Float
96.63%
Yield 2026 *
2.07%
Yield 2027 * 2.2%
1 day+0.88%
Current month+74.00%
Current year+75.59%
Current year 89.04
Extreme 89.04
162.18
1 year 72.9
Extreme 72.895
162.18
3 years 60.47
Extreme 60.47
162.18
5 years 52.65
Extreme 52.65
162.18
10 years 25.55
Extreme 25.55
162.18
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%-4.85% - - 249B
-0.52%+3.21%+85.02%+161.12% 1,057B
+0.88%+1.13%+51.13%+49.76% 625B
+0.89%-1.95%+23.73%+63.67% 435B
+0.71%+3.87%+47.45%+38.68% 363B
+0.64%-0.49%+35.39%+40.21% 296B
+0.39%-5.83%+8.64%+9.28% 249B
+1.51%+6.69%+44.34%+62.47% 222B
+3.92%-0.46%-1.21%-44.09% 209B
+1.80%+2.30%+20.79%+65.13% 165B
Average +1.27%+0.87%+35.03%+49.58% 402.31B
Weighted average by Cap. +1.11%+1.22%+48.34%+75.33%

Financials

2026 *2027 *
Net sales 63.27B 54.73B 51.11B 46.89B 88.18B 6,022B 89.59B 600B 235B 3,018B 238B 232B 9,978B 66.85B 57.83B 54B 49.54B 93.17B 6,362B 94.65B 634B 249B 3,189B 251B 246B 10,542B
Net income 12.07B 10.44B 9.75B 8.94B 16.82B 1,149B 17.09B 114B 44.9B 576B 45.33B 44.33B 1,903B 13.72B 11.86B 11.08B 10.16B 19.12B 1,305B 19.42B 130B 51.02B 654B 51.5B 50.38B 2,163B
Net Debt 19.78B 17.11B 15.98B 14.66B 27.57B 1,883B 28.01B 187B 73.58B 944B 74.28B 72.65B 3,119B 12.31B 10.65B 9.94B 9.12B 17.15B 1,171B 17.43B 117B 45.78B 587B 46.22B 45.21B 1,941B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-08-07 $161.42 +0.22% 3,720,556
26-08-06 $161.07 -0.27% 2,353,907
26-08-05 $161.50 +3.78% 7,002,934
26-08-04 $155.62 -1.49% 8,095,274
26-08-03 $157.97 -6.88% 16,313,047
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
160.54USD
Average target price
211.41USD
Spread / Average Target
+31.69%

Quarterly revenue - Rate of surprise